Tissue treatment compositions

Abstract

A tissue treatment composition, especially an adhesive composition comprises (i) fibrin or fibrinogen and (ii) a biodegradable and biocompatible polymer capable of forming a viscous aqueous solution. In addition to glueing, the tissue adhesive composition may be used for slow-release of a drug incorporated into it or for anti-adherence purposes, for wound healing, etc.

1 . A tissue treatment composition comprising (i) fibrin or fibrinogen and (ii) a biodegradable and biocompatible polymer capable of forming a viscous aqueous solution.  
     
     
         2 . A tissue treatment composition according to  claim 1 , characterized in that constituent (i) comprises fibrin or fibrinogen and Factor XIII.  
     
     
         3 . A tissue treatment composition according to  claim 1  or  2 , characterized in that it is a two-component composition to be mixed at the time of application thereof, one component comprising fibrinogen and the other thrombin, said viscous polymer being contained in one or both of said two components.  
     
     
         4 . A tissue treatment composition according to  claim 1 ,  2  or  3 , characterized in that said fibrinogen comprising component additionally contains at least one additional member selected from Factor XIII, fibronectin, a plasmin inhibitor, a plasminogen activator inhibitor, and plasminogen.  
     
     
         5 . A tissue treatment composition according to  claim 3  or  4 , characterized in that said thrombin comprising component additionally contains bivalent calcium.  
     
     
         6 . A tissue treatment composition according to any one of  claims 3  to  5 , characterized in that said viscous polymer is contained in the fibrin or fibrinogen comprising component.  
     
     
         7 . A tissue treatment composition according to any one of  claims 1  to  6 , characterized in that said viscous polymer is a high molecular polysaccharide or proteoglycan.  
     
     
         8 . A tissue treatment composition according to  claim 7 , characterized in that said high molecular polysaccharide is selected from the group consisting of xanthan, dextran, cellulose and glycosaminoglycans, and salts and derivatives thereof.  
     
     
         9 . A tissue treatment composition according to  claim 8 , characterized in that said high molecular glycosaminoglycan is hyaluronic acid or a salt or derivative thereof.  
     
     
         10 . A tissue treatment composition according to any one of  claims 1  to  9 , characterized in that the viscosity of the mixed composition when applied is in the range of about 500 to about 1,000,000 cP, preferably about 1,000 to about 500,000 cP.  
     
     
         11 . A tissue treatment composition according to any one of  claims 3  to  10 , characterized in that one of said components is supported on a solid matrix or carrier material.  
     
     
         12 . A tissue treatment composition according to any one of  claims 9  to  11  for the administration of hyaluronic acid or a salt or derivative thereof.  
     
     
         13 . A tissue treatment composition according to any one of  claims 1  to  12 , characterized in that it is in deep-frozen or lyophilized form or in the form of a film or sheet which may be pre-formed.  
     
     
         14 . A tissue treatment composition according to any one of the preceeding claims, characterized in that it is a tissue adhesive composition.  
     
     
         15 . An anti-adherence composition, characterized in that it comprises a tissue treatment composition according to any one of  claims 1  to  14 .  
     
     
         16 . A slow-release drug formulation, characterized in that it comprises a tissue treatment composition according to any one of  claims 1  to  14 .  
     
     
         17 . A slow-release drug formulation according to  claim 16 , characterized in that the therapeutical substance is said viscous polymer itself or a species coupled thereto.  
     
     
         18 . A composition for promoting wound healing, characterized in that it comprises a tissue treatment composition according to any one of  claims 1  to  14 .  
     
     
         19 . A composition for the prevention of adhesion and scar formation, characterized in that it comprises a composition according to any one of  claims 1  to  14 .  
     
     
         20 . A composition for coating prosthetic materials or as carrier of cellular transplants, characterized in that it comprises a composition according to any one of claims  1  to 14.  
     
     
         21 . A composition according to any one of  claims 17  to  20 , characterized in that it additionally comprises at least one wound healing promoting protein.  
     
     
         22 . A composition according to  claim 21 , wherein said at least one wound healing promoting protein is selected from the group consisting of serum proteins, tissue growth factors, hormones, chemotactic proteins, and nutritional proteins.  
     
     
         23 . Use of a composition according to any one of  claims 1  to  14  as an anti-adhesive composition.  
     
     
         24 . Use of a composition according to any one of  claims 1  to  14  as s slow-release drug formulation.  
     
     
         25 . Use of a composition according to any one of  claims 1  to  14  as a wound healing composition.  
     
     
         26 . Use of a composition according to any one of  claims 1  to  14  for coating prosthetic materials.  
     
     
         27 . Use of a composition according to any one of  claims 1  to  14  as a carrier of cell transplants.